Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
This test measures the activity of Factor XII, a clotting protein that helps start the contact portion of the intrinsic pathway of blood clotting. It is a functional assay that evaluates how well Factor XII works in your plasma.
Doctors often order this test to investigate a prolonged activated partial thromboplastin time (aPTT) or to look for inherited or acquired changes in Factor XII. It can be run alongside tests for other clotting factors to clarify the cause of abnormal screening results.
Understanding your Factor XII activity can help explain an abnormal aPTT and guide safe decisions about procedures or treatments. Low activity of this factor typically does not cause bleeding, but it can make clotting screens look abnormal and complicate monitoring with certain blood thinners.
Results can also point to conditions that affect clotting proteins, such as liver disease or the presence of antibodies that interfere with phospholipid-dependent clotting tests. Your clinician may combine this result with other tests to determine whether additional evaluation or changes in management are needed.
If your Factor XII activity is lower than expected, it may explain an abnormal aPTT without meaning you are at increased bleeding risk. Your clinician may repeat testing, review your medications, assess liver function, or consider genetic testing if a lifelong deficiency is suspected.
Higher than expected activity is usually not concerning on its own and can be seen with inflammation, pregnancy, or estrogen therapy. Your result should be interpreted in the context of your health history and other laboratory findings. Do not stop or start medicines without medical advice.
If the pattern suggests an inhibitor or lupus anticoagulant, your care team may order mixing studies, antiphospholipid antibody testing, or additional factor assays. These steps help confirm the cause of the abnormal result and guide follow-up.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
The citrate tube must be properly filled and mixed, and testing should occur promptly. Underfilling, clots in the tube, prolonged transport, or improper storage can artifactually lower measured activity.
Heparins and some direct oral anticoagulants can interfere with clot-based factor assays and make activity appear lower. Tell your care team and the laboratory about all blood thinners you take.
Antiphospholipid antibodies and certain inhibitors can affect phospholipid-dependent assays, sometimes mimicking a factor deficiency. Mixing studies or alternative methods may be needed to clarify results.
Factor XII is produced in the liver. Significant liver disease can reduce levels and activity, so liver tests and clinical context are important when interpreting results.
Estrogen therapy, pregnancy, and inflammatory states can change Factor XII activity. Your clinician will consider these physiologic influences when reviewing your result.
Some people are born with low Factor XII activity. This usually does not cause bleeding, but it can prolong screening clotting times. Family history and repeat testing can help confirm the pattern.
References